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ABstrAct
New Onset Diabetes after Transplantation (NODAT) is a common complication of  renal transplantation worldwide. 
However, there is very little data available regarding this condition in Sub-Saharan Africa. This study was therefore 
conducted in order to determine the incidence of  NODAT and its associated risk factors in a South African renal 
transplant population. A retrospective analysis was conducted on 221 patients who underwent renal transplants at 
Tygerberg Hospital during the period January 1st 1995 to December 31st 2008. 
Specific information was retrieved from patient files in order to determine the study outcomes. Fifty of  the 221 patients 
were found to have NODAT reflecting an incidence of  22.6% (95% CI 0.17-0.28). The cumulative incidences of  NODAT 
at three, 12 and 36 months were 9%, 12% and 17% respectively. The mean time to onset of  NODAT was 18 months 
after transplantation (95% CI 11.3-25.3) and the mean age at diagnoses of  NODAT was 41 years (95% CI 38.9-44.8). 
Transplantation at the age of  40 years (odds ratio = 1.05) as well the usage of  tacrolimus (odds ratio = 0.43) was found 
to increase the risk of  developing NODAT. The development of  NODAT did not have any effect on graft or patient 
survival in this study.
The incidence of  NODAT in a South African population appears to be as high as it is worldwide with the first year post-
transplantation carrying the greatest risk for its development. The risk for development of  NODAT is increased as the 
time post-transplantation increases. Transplantation from the age of  40 years and the use of  tacrolimus appear to be the 
most significant risk factors.
BAcKgrounD
The annual incidence of  end-stage renal disease varies 
from 100 per million population in the United Kingdom 
to 336 per million population in the United States [1]. The 
incidence of  chronic kidney disease in Sub-Saharan Africa 
is estimated to be three to four times higher than in more 
developed countries [2]. It is a well-established fact that renal 
transplantation is the best form of  renal replacement therapy. 
Renal transplant recipients have a longer life expectancy than 
patients who receive any form of  dialysis (8.17 years versus 
4.32 years) and are less likely to develop cardiovascular and 
cerebrovascular disease [3] – this reference reflects elderly 
patients. Transplantation also improves the quality of  life 
(QOL) in large groups of  patients when compared to those 
on dialysis [4].
Complications commonly occur after renal transplantation. 
Amongst those is New Onset Diabetes after Transplantation 
(NODAT). Studies have shown an association with the 
increased risk of  cardiovascular disease in transplant 
recipients which ultimately is a major cause of  myocardial 
infarction and death in renal transplant recipients [5-7]. 
NODAT reduces both graft and patient survival and is also 
an independent predictor of  death-censored graft failure [8-
10].
The incidence of  NODAT increases as the time after 
transplantation increases [4]. Its cumulative incidences at 
three, 12 and 36 months post-renal transplantation is about 
9%, 12% and 24% respectively [11, 12]. Incidence of  NODAT 
varies amongst population groups and various institutions 
worldwide. In the United States two studies at different 
centres showed similar figures. The incidence ranged from 
9.1% to 24% versus 5.9% to 29.8% (the variation was due 
to different incidence rates at different periods of  time) [11, 
12]. In a UK study the incidence ranged from 15% to 20% 
[11]. The incidences are very similar in most studies [11-17].
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The consequence of  NODAT is an increase in the costs 
required for management of  this already expensive group of  
patients. In the United States the costs of  treating transplant 
recipients who develop NODAT is estimated to be $12,000 
more (per patient) than for patients without diabetes in the 
first year post transplant and $20,000 more by the end of  
the second year post transplant [18,19]. There is very little 
variation in costs when comparing patients using different 
forms of  immunosuppressive therapy [18]. More important 
is the effect on patient and graft survival. Graft survival is 
reduced due to the development of  diabetic nephropathy 
and hypertension and patient survival is reduced due to 
an increased incidence of  opportunistic infections and 
cardiovascular disease [19, 20]. Patient survival has also been 
shown to be significantly reduced. In a study by Demirci et 
al, the 10-year mortality of  patients with NODAT was nearly 
twice that of  non-diabetic transplant recipients [14]. It is not 
surprising that quality of  life in this unique group of  patients 
is adversely affected [21].
Not all patients develop NODAT but many studies have 
identified risk factors associated with the development of  
this condition. These risk factors include: African American 
ethnicity, body mass index (BMI) more than 30kg/m2, age at 
transplantation, family history of  diabetes, impaired glucose 
tolerance pre-transplant, metabolic syndrome, recipient 
of  deceased donor kidneys, immunosuppressive therapy 
including corticosteroids and tacrolimus, Hepatitis C virus 
infection, and autosomal dominant polycystic kidney disease 
[11-17, 19, 22-23].
Data on NODAT in Sub-Saharan Africa is limited. In the only 
Southern African retrospective study done at Johannesburg 
General Hospital by Harrichund et al, the incidence of  
NODAT was found to be 15.6% with a mean time to onset 
of  22.9 months [24]. The highest incidence was found to 
be amongst Black patients with the use of  tacrolimus as an 
immunosuppressive agent [24]. These findings fall in line 
with worldwide trends.
The aims of  this study were therefore to determine the 
incidence of  NODAT amongst renal transplant recipient 
patients at Tygerberg Hospital, whether the patient 
population with NODAT fit the risk profile described in the 
literature, and to examine the effect of  NODAT on the time 
to graft failure or death.
MethoDs
Files of  patients who had renal transplants during the period 
January 1st 1995 to December 31st 2008 were retrieved for a 
retrospective analysis. Patients who received renal transplants 
at Tygerberg Hospital during this period were identified and 
included in the study. Those who had diabetes mellitus prior 
to transplantation and those transferred to other hospitals 
for follow up were excluded.
Files were obtained from the Renal Transplant Clinic (living 
patients), the Renal Unit’s Archives, and the Tygerberg 
Hospital Medical Records department. The following 
information was extracted from the folders: presence or 
absence of  NODAT, age at transplant, weight at transplant, 
plasma glucose at transplant, gender, race, time from 
transplant to diagnoses of  NODAT, number of  extra 
steroid pulses, calcineurin inhibitor used, type of  transplant, 
number of  transplants, weight at diagnoses of  NODAT, age 
at diagnoses of  NODAT, time to graft failure, and time to 
death.
In this study the diagnosis of  NODAT was based on the 
current World Health Organization criteria for diabetes 
mellitus (25):
Fasting plasma glucose ≥7.0mmol/l (126mg/dl) or 2-hour 
plasma glucose ≥11.1mmol/l (200mg/dl)
The primary objective of  the study to describe the 
incidence of  NODAT in the Tygerberg patient population 
was presented by means of  proportions and appropriate 
95% confidence intervals for proportions. The secondary 
objective to determine whether the patients fit the risk 
profile described in previous literature was presented by 
means of  the student’s t-test and the Mann-Whitney U 
test. A chi-squared analysis was used to determine any 
association between the presence or absence of  a risk factor 
and NODAT. Odds ratios were calculated after univariate 
and multivariate logistic regression analysis of  possible risk 
factors.
results
Three hundred and forty-seven patients had renal transplants 
during the study time period. Of  these, only 245 patient 
files were found. Twenty-four patients were excluded 
from the study. Seventeen had diabetes mellitus prior to 
transplantation and seven were transferred to other hospitals 
for follow up. The eventual study cohort consisted of  221 
patients (Figure 1).
The gender distribution was 106 males and 115 females. In 
terms of  race, 152 were Coloured (mixed race), 33 Black, 
31 White and five Asian. One hundred and eighty-seven 
patients received cadaveric transplants, 33 received living 
related transplants and one patient received a living unrelated 
transplant. Calcineurin inhibitors used were cyclosporine 
in 173 patients, tacrolimus in 42 patients and sirolimus in 
five patients. One hundred and ninety-one patients received 
a total of  one transplant, 23 received two transplants and 
six received three transplants. Baseline characteristics are 
summarised in Table 1. 
Fifty of  the 221 patients were found to have NODAT 
reflecting an incidence of  22.6% (95% CI 0.17-0.28) (Figure 
2). The cumulative incidences of  NODAT at three, 12 and 
36 months were 9%, 12% and 17% respectively (Figure 
2). The mean time to onset of  NODAT was 18 months 
(95% CI 11.3-25.3) after transplantation and the mean age 
at diagnoses of  NODAT was 41 years (95% CI 38.9-44.8) 
(Figure 3). A mean increase in weight from the time of  
transplantation to the diagnoses of  NODAT of  7.7kg (95% 
CI 2.8-12.6) was also found in the NODAT group.
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In the group who developed NODAT, 25 patients were male 
and 25 female. Of  these, 34 patients were Coloured, eight 
White, seven Black and one Asian. Calcineurin inhibitors 
used in the NODAT group were cyclosporine in 32 patients, 
tacrolimus in 15 patients and sirolimus in three patients. 
Forty-one patients received cadaveric renal transplants while 
only nine received living related transplants. These findings 
have been summarised in Table 2.
The NODAT group of  patients was compared to the non-
NODAT group in order elicit any significant differences 
in risk factors and long term outcome. The student’s t-test 
was used to compare the mean age at transplant and mean 
weight at transplant between the two groups. In terms of  
age a statistically significant difference was found between 
the two groups. The mean age at transplant in the NODAT 
group was 40 years while in the non-NODAT group it was 
37 (p = 0.03) (Figure 4). There was also a difference in the 
mean weight at transplant between the two groups but this 
was not statistically significant.
The Mann-Whitney U test was used to compare the average 
number of  steroid pulses, average number of  transplants, 
average time to graft failure as well as average time to death 
between the groups but none of  these showed any statistical 
significance.
Chi-squared tests were used to identify risk factors for 
NODAT which were then evaluated by means of  multivariate 
logistic regression analysis. Results of  this analysis showed 
that the following risk factors proved to be statistically 
significant: average age at transplant, average weight at 
transplant and the type of  calcineurin inhibitor used. These 
risk factors were entered into a multivariate model and odds 
ratios were calculated. The results showed that an average 
age at transplant of  40 years (odds ratio = 1.05), as well the 
usage of  tacrolimus (odds ratio = 0.43) increases the risk 
of  developing NODAT. The average weight at transplant 
of  70kg as a risk factor for NODAT was found not to be 
statistically significant (odds ratio = 1.0).
Discussion
In this study the incidence of  NODAT at Tygerberg Hospital 
was found to be 22.6% with cumulative incidences at three, 
12 and 36 months of  9%, 12% and 17% respectively. This 
is in keeping with incidences which have been reported in 
previous studies from the USA, UK, Asia as well as Southern 
Africa [11-16, 26]. The mean time to onset of  NODAT was 
18 months. This is similar to a previous Southern African 
study but does not fall in line with other previous worldwide 
studies which have shown median times to onset of  NODAT 
to be much earlier [8, 13-15, 17, 24, 26]. This may be due 
to differences in the populations represented in the various 
studies. It must be noted that despite showing a mean onset 
of  18 months, most patients (50%) developed NODAT 
within the first 10 months after transplantation – and this 
may be in keeping with other studies (Figure 3).
A mean age at transplantation of  40 years was found to be 
a significant risk factor for the development of  NODAT 
compared to patients who did not develop NODAT having 
a mean age of  37. The difference in age at transplantation 
between the two groups was not as great as described by 
Harrichund et al but still is significant [24]. Many previous 
studies also described age as a significant risk factor for the 
development of  NODAT [11, 12, 16, 17, 19, 26]. The mean 
age at transplantation of  40 years, combined with the fact 
that half  of  the patients developed NODAT within one year 
after transplantation, probably explains why the average age 
at diagnoses of  NODAT in this study was 41 years. It must be 
noted that patients who are accepted for renal replacement 
at Tygerberg Hospital are significantly younger than patients 
in the private sector or in other first world settings, and this 
is due to stringent selection criteria and limited financial 
resources.
This study also found that the use of  calcineurin inhibitors, 
specifically tacrolimus (when compared to cyclosporine) was 
a significant risk factor for the development of  NODAT. 
This falls in line with most previous studies worldwide [12-
14, 19, 24, 27, 28]. A meta-analysis comparing the effects 
of  tacrolimus and cyclosporine was done by Webster et 
al [29]. In this systematic review tacrolimus was favoured 
over cyclosporine as it showed improved survival rates, 
decreased incidences of  acute rejection and lower mean 
creatinine levels at six months post-transplantation [29]. No 
difference was found between the two drugs in the incidence 
of  opportunistic infections or malignancies. Both drugs had 
various side effects but as expected the meta-analysis showed 
an increased risk of  NODAT with tacrolimus. 
In a study comparing cost effectiveness between the two 
drugs in the United Kingdom, tacrolimus was found to be 
the more cost effective option even though the long term 
costs were higher due to its superior overall survival, survival 
with a functioning graft and rejection-free survival [30]. 
Evidence is emerging that despite its costs and possible 
adverse effects, tacrolimus is the favoured drug as its benefits 
by far outweigh its risks.
At Tygerberg Hospital, patients are started on cyclosporine 
in addition to prednisone and azathioprine as primary 
immunosuppression after renal transplantation. Patients are 
changed to tacrolimus only if  they experience severe adverse 
effects due to cyclosporine or if  they develop steroid-
resistant acute rejection. It is for this reason that only 19% 
of  the study patients received the drug. However, evidence 
is emerging worldwide for tacrolimus to be used as a first-
line immunosuppressant and this practice may eventually be 
implemented in South Africa.
The addition of  extra steroid pulses for treatment of  acute 
rejection was not found to be a risk factor for the development 
of  NODAT unlike the findings of  other studies [10, 26].
Black people have been identified as a risk for NODAT in 
most previous studies [11, 12, 19, 24, 28]. The same was not 
found in this study possibly due to the fact that the patient 
population was not as racially diverse as in other studies or 
that the genetic predisposition of  South African Blacks to 
the development of  diabetes mellitus is different to Black 
patients in other first world countries. Harrichund et al 
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showed similar results [24]. The fact that the number of  
Black patients in this study were so small (15%) is another 
reason for them not being identified as a significant risk 
factor for the development of  NODAT. It is noteworthy 
that eight (53%) of  the 15 Black patients who received renal 
transplants at Tygerberg Hospital developed NODAT. A 
future study which includes more Black renal transplant 
patients may expose this risk factor as significant for the 
development of  NODAT in a South African population.
There was no variation with gender for the development 
of  NODAT. The study population consisted of  an equal 
number of  males and females and this was also reflected 
amongst those who developed NODAT (Tables 1, 2). 
Gender was therefore not considered a risk factor for the 
development of  NODAT. Other studies have also shown 
the same results [13-16].
This study did not show that recipients of  cadaver kidneys 
were more at risk for NODAT than patients who received 
living related transplants as shown in other studies [11, 12, 
19, 24, 28]. This may be due to the relatively small number 
of  living related transplants amongst the study population 
(15%).
Several studies have also shown that body mass indexes of  
more than 30kg/m2 as well as a family history of  diabetes 
mellitus are independent risk factors for NODAT [11, 12, 
15, 16, 23, 24]. This study was inconclusive in terms of  
these risk factors as patient heights pre transplantation were 
never recorded and therefore it was not possible to calculate 
the body mass index for each patient. Most patient records 
were also not clear in terms of  family history of  diabetes. 
This study however shows a clear association between 
NODAT and an increase in weight of  7.7kg from the time 
of  transplantation to the diagnoses thereof.
There have been studies looking at the pre-existing renal 
disease as a risk factor for the development of  NODAT. 
Specifically, autosomal dominant polycystic kidney disease 
(ADPKD) has been found to be a risk factor for its 
development [22, 23]. Our study was unable to determine 
any association between the two conditions as there were 
limited numbers of  patients (only 10 patients in the study 
had ADPKD) with this disease included in the study.
The influence of  dialysis modality prior to transplantation 
has also been studied recently. Courivard et al determined 
that the dialysis modality pre transplantation had no 
influence on the development of  post-transplant diabetes 
mellitus [31, 32]. In contrast, a study by Madziarska et 
al found that peritoneal dialysis appears to be a possible 
novel risk factor which may increase the risk of  NODAT 
development [33]. At Tygerberg Hospital the majority 
of  patients are started on peritoneal dialysis and are then 
transferred to haemodialysis within an average time of  18 
months due to failure of  the peritoneal membrane (personal 
communication, Dr R Adeniyi, Tygerberg Hospital Renal 
Unit). Most patients therefore underwent both forms of  
dialysis before transplantation which made it difficult to 
draw any conclusions regarding the impact of  peritoneal 
dialysis on the development of  NODAT in our transplant 
population.
Hepatitis C virus infection has been shown to be an 
independent risk factor for the development of  NODAT in 
many studies [11-14,16,19]. In one study the prevalence of  
Hepatitis C as a risk factor for NODAT was particularly high 
in patients using tacrolimus [14]. However the exact reason 
for this association is not presently understood. During the 
study period no transplants were performed on Hepatitis C 
positive patients and it could therefore not be examined as a 
risk factor for NODAT.
The effect of  NODAT on graft and patient survival was 
examined in this study as previous studies have shown 
that it reduces both [8-11, 26, 34]. There was no difference 
found between time to graft failure or time to death between 
patients with NODAT and those without. Therefore in this 
population no clear effect was shown in terms of  graft and 
patient survival. This again is similar to what was shown by 
Harrichund et al [24].
Recent studies with regards to NODAT have looked at 
the existence of  genetic polymorphisms in renal transplant 
recipients, some of  which are thought to be protective 
against NODAT and others which have been implicated as 
causative factors for its development. Plasminogen activator 
inhibitor-1 5G/5G genotype homozygosity has been 
associated with a significantly lower rate of  development of  
NODAT and is thought to be protective [35]. Dutkiewicz 
et al found that a polymorphism of  the GPX1 gene may 
be associated with the development of  NODAT in Polish 
subjects [36]. In Korea, studies have implicated various 
genetic polymorphisms as risk factors for the development 
of  NODAT. These include: CCL5, TCF7L2, SLC30A8, 
HHEX, CDKAL1 and many others [37-39]. Many other 
studies are looking at genetic polymorphisms in an attempt 
to better understand the disease process. Due to financial 
constraints and the retrospective nature of  this study the role 
of  genetic polymorphisms was not examined.
conclusion
The incidence of  NODAT in a South African population 
appears to be as high as it is worldwide with the first year 
post-transplantation carrying the greatest risk for its 
development. The risk for development of  NODAT is 
increased as the time post-transplantation increases. An 
age of  40 years or older at transplantation and the use of  
tacrolimus appear to be the most significant risk factors. 
An increase in weight of  7.7kg post-transplantation may be 
associated with the development of  NODAT. This study 
did not identify race, gender or cadaveric transplants as risk 
factors for the development of  NODAT. NODAT was not 
shown to reduce graft failure or patient survival.
The findings of  this study closely reflect what was found 
in the only other South African study looking at NODAT 
by Harrichund et al [24]. Similar incidences and risk factors 
were found in that study. However, similarities are also seen 
with many of  the first world NODAT studies and this may 
reflect the lifestyle changes in the South African population 
which may have lead to the increased development of  
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diabetes mellitus amongst all patients including those who 
underwent renal transplantation.
The roles of  genetic polymorphisms as risk or protective 
factors are becoming more evident with more research being 
done in this field. These polymorphisms may eventually be 
used as potential treatment targets for the prevention or 
treatment of  NODAT in the future. However, more research 
in this field is required.
stuDy liMitAtions
As this was a retrospective study from patient records, 
the data retrieved was not always complete. For example, 
body mass index could not be calculated as heights were 
not done on all patients’ pre-transplantation and family 
history of  diabetes mellitus was not always recorded in the 
notes. Hepatitis C as a risk factor for NODAT could not 
be evaluated in this study. A number of  files were missing 
resulting in the patient cohort being smaller than expected. 
However, despite the relatively high dropout rate the results 
obtained were still of  statistical significance. 
recoMMenDAtions
Pre-transplant screening of  patients in terms of  family 
history of  diabetes mellitus, body mass index, impaired 
glucose tolerance and patient age should be mandatory in 
all patients. This would aid in identifying patients who are 
at risk to develop NODAT. More intensive screening and 
appropriate management can then be instituted at an early 
stage. Post-transplantation patients should be monitored 
strictly in terms of  fasting plasma glucose weekly for the first 
four weeks post-transplantation, then every three months 
for one year and annually thereafter [40]. Patients who have 
developed NODAT should be treated according to normal 
guidelines for diabetes mellitus.
Aspirin has been recommended in these patients at a dosage 
of  65-100mg/day for primary prevention for cardiovascular 
disease [40]. Aspirin therapy has been found to be beneficial 
after myocardial infarction even in patients who have chronic 
kidney disease and may have uremic platelet dysfunction [41]. 
It has also been associated with improved allograft function 
and survival [41]. However, it is important to note that the 
cardio protective effect of  aspirin is limited mainly by the 
risk for serious gastrointestinal bleeding, a risk that may be 
higher in renal transplant recipients [41]. Therefore aspirin 
should be used with caution and at a low dosage.
A prospective study to address the shortfalls of  this study is 
recommended, to provide a more detailed evaluation of  this 
condition.
Any comments on early use of  basal insulin and potential 
place of  new oral diabetic drugs like Vildagliptin?
ADDenDuM: figures AnD tABles
Figure 1: Patient selection
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Figure 2: Incidence of NODAT
Figure 2 shows an incidence of  NODAT of  23% in the Tygerberg population.
Figure 3: Time from transplant to development of NODAT
Figure 3 shows that although the mean time to onset of  NODAT was 18 months, most patients developed the condition within the first year 
post-transplantation.
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Figure 4: Age at transplant (p = 0.03) (Student’s t-test)
Figure 4 shows a statistically significant difference in the mean age at transplant between patients with and without NODAT – 40 years of  age 
in the NODAT group versus 37 years in the Non-NODAT group.
Table 1: Baseline characteristics
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Table 2:  Patient characteristics: NODAT vs Non-NODAT
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